CN Mobile Logo

Search form


Pediatric Cancers

Pediatric Cancers

The FDA has granted priority review status for two new indications of dasatinib (Sprycel), according to the drug’s developer.

The FDA has expanded the approval of blinatumomab (Blincyto) for the treatment of relapsed or refractory B-cell precursor acute lymphoblastic leukemia in adults and children.

Dasatinib was safe and effective in pediatric patients with chronic myeloid leukemia, according to a new study, establishing the agent as a new standard of care for this population.

Significant improvements in treatment protocols have reduced the incidence of serious chronic late health effects in survivors of childhood cancer treatment.

There is considerable value in having achieved a minimal residual disease negativity for pediatric and adult patients with acute lymphoblastic leukemia.

Female survivors of childhood acute lymphoblastic leukemia were at risk for neurocognitive impairment and were more susceptible to the effects of sleep disturbance and fatigue compared with their male counterparts.

Younger cancer survivors experience worse survival outcomes following a second primary cancer diagnosis than their older counterparts, according to a recent study.


Subscribe to Pediatric Cancers on [sitename]

By clicking Accept, you agree to become a member of the UBM Medica Community.